<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00895479</url>
  </required_header>
  <id_info>
    <org_study_id>Ark 103</org_study_id>
    <nct_id>NCT00895479</nct_id>
  </id_info>
  <brief_title>Adenovirus Vascular Endothelial Growth Factor (VEGF) Therapy in Vascular Access - Novel Trinam AGainst Control Evidence</brief_title>
  <acronym>AdV-VANTAGE</acronym>
  <official_title>A Phase III, Randomized, Controlled, Open Label, Multicenter Study of the Efficacy and Safety of Trinam® (EG004); an Assessment of Primary Unassisted Patency and Survival of Vascular Access Grafts in Hemodialysis Patients With End Stage Renal Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ark Therapeutics Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ark Therapeutics Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients in renal failure on hemodialysis depend on adequate and sustained vascular access.&#xD;
      This can be achieved by surgical placement of a synthetic polytetrafluoroethylene (PTFE)&#xD;
      graft. These patients frequently experience graft complications arising from the development&#xD;
      of smooth muscle cell (SMC) neointimal hyperplasia in the proximity of the graft-vein&#xD;
      anastomosis. Such complications eventually lead to stenosis, access thrombosis and graft&#xD;
      failure. Trinam® is being developed to prolong graft survival. It is a combination product&#xD;
      consisting of a replication deficient Adenovirus containing the human Vascular Endothelial&#xD;
      Growth Factor D (Ad-VEGF-D) gene and a biodegradable local delivery device (collar) made of&#xD;
      collagen. At the end of the surgical procedure to insert the PTFE graft the collagen collar&#xD;
      is applied around the anastomosis and sealed with a collagen surgical sealant. This procedure&#xD;
      creates a reservoir between the site of anastomosis and the collagen collar. The adenoviral&#xD;
      vector is then injected into this reservoir, localizing the expression of the transgene to&#xD;
      the site of the anastomosis. Expression of VEGF-D has been shown to have a vascular&#xD;
      protective role and inhibit SMC neointimal proliferation, therefore expression of VEGF-D&#xD;
      should prolong graft survival.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Strategic reasons. Seeking partner for future development.&#xD;
  </why_stopped>
  <start_date>April 2009</start_date>
  <completion_date type="Anticipated">September 2011</completion_date>
  <primary_completion_date type="Anticipated">September 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Unassisted Patency</measure>
    <time_frame>18 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Graft Survival. Number and rate of graft interventions.</measure>
    <time_frame>2.5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>Trinam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Graft placement plus Trinam therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Graft placement surgery alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Graft placement surgery plus Trinam therapy</intervention_name>
    <description>Trinam arm: graft placement surgery plus 1ml perivascular administration of Trinam vector.&#xD;
Control arm: graft placement surgery</description>
    <arm_group_label>Trinam</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with end stage renal disease undergoing either initial placement or&#xD;
             replacement (after failure of previous vascular access) of an end-to-side or&#xD;
             end-to-end 6.0 mm synthetic PTFE arteriovenous hemodialysis access arm graft.&#xD;
&#xD;
          -  Male or female aged 18 years or over.&#xD;
&#xD;
          -  Patients who signed the informed consent form.&#xD;
&#xD;
          -  Patients who are expected to undergo dialysis at nominated facilities for the duration&#xD;
             of the study.&#xD;
&#xD;
          -  Patients who have agreed to participate in the additional four year gene therapy&#xD;
             safety monitoring.&#xD;
&#xD;
          -  Patients who are willing to agree they will not have a kidney transplant for four&#xD;
             weeks post treatment with Trinam®.&#xD;
&#xD;
          -  Patients who have undergone arterial and venous mapping to ensure an adequate and&#xD;
             appropriate access site is available for placement of either an end-to-side or an&#xD;
             end-to-end 6.0 mm synthetic PTFE arteriovenous hemodialysis access arm graft with or&#xD;
             without the addition of Trinam®.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who are unable to understand and sign the consent form.&#xD;
&#xD;
          -  Patients undergoing surgical revision of an existing graft.&#xD;
&#xD;
          -  Exclude patients from the study if they have moderate or severe macular edema moderate&#xD;
             or severe proliferative diabetic retinopathy&#xD;
&#xD;
          -  Current diagnosis of cancer with exception of non-melanoma skin cancers.&#xD;
&#xD;
          -  Hepatic dysfunction defined as AST and / or ALT &gt; 2 times the Upper Limit of Normal.&#xD;
&#xD;
          -  Diabetic patients with Hemoglobin A1C value of &gt;10%.&#xD;
&#xD;
          -  White blood cell (WBC) count &lt; 2.0 x 109/L.&#xD;
&#xD;
          -  Prior anticoagulant therapy within 14 days prior to surgery is an exclusion.&#xD;
&#xD;
          -  Known sensitivity to collagen.&#xD;
&#xD;
          -  Pregnancy, lactation or lack of effective contraception both in women and in men of&#xD;
             childbearing potential.&#xD;
&#xD;
          -  Previous participation in any Trinam® study.&#xD;
&#xD;
          -  Receipt of any investigational drug within 30 days prior to study enrollment or&#xD;
             participation in any concurrently running trial involving investigational&#xD;
             intervention.&#xD;
&#xD;
          -  Any medical or psychiatric condition that compromises the ability to participate in&#xD;
             the study.&#xD;
&#xD;
          -  Known or suspected drug or alcohol abuse in the past six months.&#xD;
&#xD;
          -  Life expectancy of less than one year.&#xD;
&#xD;
          -  Known immunodeficiency disease.&#xD;
&#xD;
          -  Known chronic hepatitis of viral or non-viral etiology and / or a history of&#xD;
             decompensated liver failure of any etiology.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Long Beach VA Healthcare System</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>CA 90822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Four Rivers Clinical Research Inc</name>
      <address>
        <city>Paducah</city>
        <state>Kentucky</state>
        <zip>KY 42003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baton Rouge General Hospital</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>LA 70809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisiana State University Health Sciences Center</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>LA 71103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>MO 63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>NY 10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Luke's Roosevelt Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>NY10025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>NC 27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>OH 45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University Division of Nephrology</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>OH 43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Tech University Medical Center</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>TX 79415</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harborview Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>WA 98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <study_first_submitted>May 7, 2009</study_first_submitted>
  <study_first_submitted_qc>May 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2009</study_first_posted>
  <last_update_submitted>November 18, 2010</last_update_submitted>
  <last_update_submitted_qc>November 18, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2010</last_update_posted>
  <responsible_party>
    <name_title>Director of Research and Development</name_title>
    <organization>Ark Therapetics Ltd</organization>
  </responsible_party>
  <keyword>End Stage Renal Disease</keyword>
  <keyword>ESRD</keyword>
  <keyword>Hemodialysis</keyword>
  <keyword>Access Graft</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

